Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium–Derived Factor in Polypoidal Choroidal Vasculopathy and Choroidal Neovascularization

Tong, Jianping; Chan, Wai‐Man; Liu, David T.L.; Lai, Timothy Y. Y.; Choy, Kwong Wai; Pang, Chi‐Pui; Lam, Dennis S C

doi:10.1016/j.ajo.2005.10.012

Cited by 340 publications

(224 citation statements)

References 34 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…However, VEGF may have a role in pathogenesis. Compared with normal controls, VEGF concentrations in the aqueous were found to be markedly increased in PCV eyes 11 and strong expression of VEGF was observed in RPE cells of PCV specimens. 12 These reports support the use of anti-VEGF treatment of PCV eyes.…”

Section: Introductionmentioning

confidence: 76%

“…Although the pathophysiology of PCV is not completely understood, resolving subretinal hemorrhage and decreasing leakage from PCV lesions may be an important and reasonable approach to stabilization of visual acuity. Moreover, VEGF concentrations in the aqueous were found to be markedly increased in PCV eyes 11 and strong expression of VEGF was observed in RPE cells of PCV specimens. 12 These points of view support anti-VEGF treatment for PCV eyes.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Cho

Kim

Lee

et al. 2011

Eye

View full text Add to dashboard Cite

Purpose To compare the effectiveness of intravitreal injection of bevacizumab and ranibizumab in patients with treatment-naïve polypoidal choroidal vasculopathy (PCV). Methods A total of 66 and 60 eyes of 121 consecutive patients who received intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg) injection for treatment of PCV were retrospectively reviewed. After initial three loading injections by month, injection was performed as needed. Main outcome measures included best corrected visual acuity (BCVA), foveal center thickness (FCT) as assessed by spectral domain optical coherence tomography (SD-OCT), and change in polypoidal lesion on indocyanine green angiography (ICGA). Results At 12 months, average number of injections was 4.72±1.84 in the bevacizumab group and 5.52±1.54 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline at 12 months after injection improved by 0.11 in the bevacizumab group (P ¼ 0.02) and by 0.14 in the ranibizumab group (P ¼ 0.01). Average FCT decreased from 368±62.48 to 298±40.77 lm in the bevacizumab group (P ¼ 0.01) and from 371±50.79 to 286±36.93 lm in the ranibizumab group (P ¼ 0.01). Polyp regression rate was 24.2% (16 eyes out of 66 eyes) in the bevacizumab group and 23.3% (14 eyes out of 60 eyes) in the ranibizumab group. There was no statistically significant difference in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. Conclusion Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilization of visual acuity, macular edema, and regression of polypoidal complex with PCV eyes.

show abstract

Section: Introductionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 94%

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Cho

Kim

Lee

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…7 The presence of high levels of vascular endothelial growth factor and pigment epithelium-derived factor is suspected to be involved in the development of myopic CNV. 22 Antiangiogenic therapies (isolated or in association with PDT) have been used to treat subfoveal myopic CNV such as intravitreous 9,10,23,24 triamcinolone or intravitreous bevacizumab. [11][12][13][14][15][16][17][18][19][20] To our knowledge, no reports on the use of pegaptanib or ranibizumab (the only approved drugs for intravitreal use) have been published and no clinical trials are underway.…”

Section: Discussionmentioning

confidence: 99%

Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results

Ruiz-Moreno

Gómez‐Ulla

Montero

et al. 2007

Eye

View full text Add to dashboard Cite

Aim To describe the anatomical and visual outcome of subfoveal and juxtafoveal choroidal neovascularization (CNV) in highly myopic eyes treated by intravitreal bevacizumab. Methods Prospective, nonrandomized, multicentric, interventional pilot study. Twenty-six highly myopic eyes from 25 patients with subfoveal and juxtafoveal CNV were treated by three monthly intravitreal injections with 1.25 mg bevacizumab. Patients were evaluated for best-corrected visual acuity (BCVA) and optical coherence tomography at baseline and then monthly. ) at month 6. Fifteen eyes were naïve for treatment and 11 eyes had been previously treated by photodynamic therapy (PDT) (average 2.5 PDT sessions). Leakage from CNV had ceased in all eyes at month 3 and CNV was still closed at month 6. Neither ocular nor systemic safety issues appeared during the follow-up. Conclusions Intravitreal bevacizumab seems to be an effective and safe therapeutic procedure to treat subfoveal and juxtafoveal CNV in highly myopic eyes. Further studies are required to verify the efficacy and usefulness of this therapy compared with established treatments for this condition.

show abstract

“…Mean change in macular volume from baseline over time up to month 12 was − 0.89 mm 3 . Seven (47%) of 15 patients had no evidence of subretinal OCT edema at month 12.…”

Section: Anatomic End Pointsmentioning

confidence: 95%

“…Evidence has shown that vascular endothelial growth factor (VEGF) is expressed in PCV lesions 2,3 ; thus, anti-VEGF monotherapy has been evaluated for the treatment of PCV. [4][5][6][7][8][9][10][11][12][13][14] In a previous study 7 (ClinicalTrials.gov identifier: NCT00837330), we evaluated intravitreal ranibizumab 0.3-and 0.5-mg monotherapy in 20 eyes of non-Asian patients with PCV.…”

Section: Introductionmentioning

confidence: 99%

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population

Marcus

Singh

Fechter

et al. 2015

Eye

View full text Add to dashboard Cite

Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium–Derived Factor in Polypoidal Choroidal Vasculopathy and Choroidal Neovascularization

Cited by 340 publications

References 34 publications

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy

Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results

High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population

Contact Info

Product

Resources

About